Cargando…
The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients
The dominant pathogenesis underlying the combined pulmonary fibrosis and emphysema (CPFE) remains unresolved. The receptor for advanced glycation end-products (RAGE) is highly expressed in lung tissues and interacts with distinct multiple ligands, implicating it in certain lung diseases. To elucidat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393115/ https://www.ncbi.nlm.nih.gov/pubmed/32732977 http://dx.doi.org/10.1038/s41598-020-69184-8 |
_version_ | 1783564978226200576 |
---|---|
author | Kinjo, Takumi Kitaguchi, Yoshiaki Droma, Yunden Yasuo, Masanori Wada, Yosuke Ueno, Fumika Ota, Masao Hanaoka, Masayuki |
author_facet | Kinjo, Takumi Kitaguchi, Yoshiaki Droma, Yunden Yasuo, Masanori Wada, Yosuke Ueno, Fumika Ota, Masao Hanaoka, Masayuki |
author_sort | Kinjo, Takumi |
collection | PubMed |
description | The dominant pathogenesis underlying the combined pulmonary fibrosis and emphysema (CPFE) remains unresolved. The receptor for advanced glycation end-products (RAGE) is highly expressed in lung tissues and interacts with distinct multiple ligands, implicating it in certain lung diseases. To elucidate the pathogenesis of CPFE, we genotyped three single nucleotide polymorphisms (SNPs: rs2070600, rs1800625, and rs2853807) of the gene encoding RAGE (AGER) in 111 CPFE patients and 337 chronic obstructive pulmonary disease (COPD) patients of Japanese by using StepOne Real-Time PCR System for SNP genotyping assay. Serum levels of soluble RAGE (sRAGE) were measured by ELISA. We found that the allele frequency of rs2070600 was significantly different between the two groups [corrected P (Pc) = 0.015]. In addition, the minor allele was associated with CPFE patients relative to COPD patients in a dominant effect model (Odds Ratio = 1.93; Pc = 0.018). Moreover, the serum sRAGE level was significantly lower in the CPFE group than the COPD group (P = 0.014). The rs2070600 minor allele was significantly associated with reduced sRAGE level in CPFE patients and independently affected sRAGE level reduction in this group (P = 0.020). We concluded that the AGER rs2070600 minor allele (Gly82Ser mutation) is associated with the pathogenesis of pulmonary fibrosis in CPFE in Japanese patients. |
format | Online Article Text |
id | pubmed-7393115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73931152020-08-03 The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients Kinjo, Takumi Kitaguchi, Yoshiaki Droma, Yunden Yasuo, Masanori Wada, Yosuke Ueno, Fumika Ota, Masao Hanaoka, Masayuki Sci Rep Article The dominant pathogenesis underlying the combined pulmonary fibrosis and emphysema (CPFE) remains unresolved. The receptor for advanced glycation end-products (RAGE) is highly expressed in lung tissues and interacts with distinct multiple ligands, implicating it in certain lung diseases. To elucidate the pathogenesis of CPFE, we genotyped three single nucleotide polymorphisms (SNPs: rs2070600, rs1800625, and rs2853807) of the gene encoding RAGE (AGER) in 111 CPFE patients and 337 chronic obstructive pulmonary disease (COPD) patients of Japanese by using StepOne Real-Time PCR System for SNP genotyping assay. Serum levels of soluble RAGE (sRAGE) were measured by ELISA. We found that the allele frequency of rs2070600 was significantly different between the two groups [corrected P (Pc) = 0.015]. In addition, the minor allele was associated with CPFE patients relative to COPD patients in a dominant effect model (Odds Ratio = 1.93; Pc = 0.018). Moreover, the serum sRAGE level was significantly lower in the CPFE group than the COPD group (P = 0.014). The rs2070600 minor allele was significantly associated with reduced sRAGE level in CPFE patients and independently affected sRAGE level reduction in this group (P = 0.020). We concluded that the AGER rs2070600 minor allele (Gly82Ser mutation) is associated with the pathogenesis of pulmonary fibrosis in CPFE in Japanese patients. Nature Publishing Group UK 2020-07-30 /pmc/articles/PMC7393115/ /pubmed/32732977 http://dx.doi.org/10.1038/s41598-020-69184-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Kinjo, Takumi Kitaguchi, Yoshiaki Droma, Yunden Yasuo, Masanori Wada, Yosuke Ueno, Fumika Ota, Masao Hanaoka, Masayuki The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients |
title | The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients |
title_full | The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients |
title_fullStr | The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients |
title_full_unstemmed | The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients |
title_short | The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients |
title_sort | gly82ser mutation in ager contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (cpfe) in japanese patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393115/ https://www.ncbi.nlm.nih.gov/pubmed/32732977 http://dx.doi.org/10.1038/s41598-020-69184-8 |
work_keys_str_mv | AT kinjotakumi thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT kitaguchiyoshiaki thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT dromayunden thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT yasuomasanori thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT wadayosuke thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT uenofumika thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT otamasao thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT hanaokamasayuki thegly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT kinjotakumi gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT kitaguchiyoshiaki gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT dromayunden gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT yasuomasanori gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT wadayosuke gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT uenofumika gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT otamasao gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients AT hanaokamasayuki gly82sermutationinagercontributestopathogenesisofpulmonaryfibrosisincombinedpulmonaryfibrosisandemphysemacpfeinjapanesepatients |